CONJUNCTIVITIS AS A RARE SIDE-EFFECT OF RISEDRONATE: A CASE REPORT

Osteoporosis is common metabolic bone disease in older people. Bisphosphonates is usually used in the management of osteoporosis. However, a small number of patients have been recognized to develop ocular inflammation due to administration of bisphosphonates. We report the case of risedronate-induced conjunctivitis in a 68-year-old woman. This was successfully treated with stopping risedronate. Applying Naranjo's adverse drug reaction probability scale, a causality assessment was made which categorized this reaction as probable with a score of 7. This case report reviews the literature on the ocular effects of risedronate and discusses a possible mechanism for the association. Although ocular adverse effects of bisphosphonates are rare, it may effect eyesight. Physical Medicine and Rehabilitation clinicians should be aware of ocular side-effects in older patients because a delay in diagnosis may result in serious adverse outcomes.